UBS initiates Amgen, Inc.(NASDAQ:AMGN ) with a Neutral and price target of $185. During the next four years Amgen sales growth will face intensifying headwinds to Enbrel and key legacy products. The late-stage pipeline,
UBS initiates Celgene Corporation(NASDAQ:CELG) with a Buy and price target of $140. Robust top-line growth has become a rarity in large-cap biotech, and against that backdrop, Celgene has and should continue to stand out
Juno Therapeutics Inc(NASDAQ:JUNO) discontinues development of JCAR015 in r/r adult ALL to focus on defined cell product in this setting (25.31 +1.27) “We continue to experience encouraging signs of clinical benefit in our trial addressing
Puma Biotechnology Inc (NASDAQ:PBYI), Shake Shack Inc (NYSE:SHAK): What Analysts Are Saying After Today’s News?
Puma Biotechnology Inc(NASDAQ:PBYI). target lowered to $17 at RBC Capital Mkts; APHINITY hits; extended adjuvant is done; 3rd-line metastatic Phase III data 1H17 (38.05) RBC Capital Mkts lowers their PBYI tgt to $17 from $48.